Scientific Program

Monday, 27 November


 07:30-17:15

 Registration 

08:50-09.00

 Congress Opening

09:00-10:30

 Session I: Opening and Keynote Presentations
   09:00-09:20  
 Lessons from High Impact Clinical Trials in 2017
 Ralph DeFronzo, USA
 
 09:20-09:40
 Innovation in Diabetes – What’s Ahead
 Stefano Del Prato, Italy

 09:40-10:00
 Changing Management Guidelines: Good  Evidence and Bad Evidence
 Philip Home, UK

 10:00-10:20
 Pragmatic and Patient-centered Studies – The Future?

 10:20-10:30
 Discussion

10:30-11:00

 Networking Break and visit the Exhibition

11:00-12:30

 Session II: Current Regulatory Trends in Diabetes and Drug Development

   11:00-11:20 
 EMA Perspective
 Giuseppe Rosano, Italy

 11:20-11:40 
 US and FDA Perspective 

 11:40-12:00 
 Industry Perspective
 James Nolan, Inclinica, USA

 12:00-12:20
 Asia/China Perspective
 Guang Ning, China

 12:20-12:30
 Discussion 

 12:30-13:30

 Lunch Break, Networking and visit the Exhibition

 13:30-15:00

 Session III: Design a Clinical Program for Success
   13:30-13:45 
 Convincing Authorities for Innovative Endpoints 

 13:45-14:00
 How New Technologies may Help in Designing Trials in Diabetes
 Paolo Pozzilli, Italy

 14:00-14:15
 The Role of DSMB (IDMC)
 Philip Home, UK

 14:15-14:30
 Clinical Trials in Emerging Nations
 Guang Ning, China

 14:30-14:45 
 Assessing and Measuring Hypoglycemia 
 Avivit Cahn, Israel

 14:45-15:00 
 Calculating, Budget and Finance
 Markolf Hanefeld, Germany

 15:00-15:30

 Networking Break and visit the Exhibition

 15:30-17:00

 Session IV

   15:30-15:50 
 Public Perception of Clinical Trials for Diabetes
 Helen Gao, Close Concerns, USA

 15:50-16:10 
 Can we Improve Retention Rates?

 16:10-16:30 
 Needs and Pitfalls of Rescue Therapy 
 Jane Reusch, USA

 16:30-16:50 
 Adjudication of outcomes and safety endpoints; is it necessary?

 16:50-17:00 
 Discussion

 17:00

 Networking Reception in the Exhibition Area


Tuesday, 28 November

 08:00-17:00

 Registration 

 09:00-10:30

 Session V: Phase 2/3 Studies
   09:00-09:15 
 Why are Phase 2 Studies so Often Misleading?
 Andreas Pfützner, Germany

 09:15-09:30 
 A Critical Look at Inclusion/Exclusion Criteria- A1C Targets and Patient  Populations 
 Roy Eldor, Israel

 09:30-09:45 
 Diabetic Neuropathy and / or  Tools to Quantify Vascular Effects in Phase Studies  and / or Biomarkers in Diabetes Studies
 Thomas Forst, Profil, Germany

 09:45-10:00 
 E-Technology for Patient Monitoring
 TBA

 10:00-10:15 
  Can Real World Evidence Substitute for RCTs to Gain Approval for New Drugs?
 Eberhard Standl, Germany

 10:15-10:30 
 Discussion

 10:30-11:45

Coffee Break, Exhibition and  Guided Poster Walks and visit the Exhibition

11:45-12:45

 Session VI: Cardiovascular Outcome Studies Part 1: What can we Learn from    Retrospective Data
   11:45-12:05 
 Merits of Observational versus Randomized Clinical Trial Data
 John Lachin, U.S.A

 12:05-12:25 
 Big Data: Advantages and Shortfalls
 Ran Goshen, Israel

 12:25-12:45 
 TBA

 12:45-13:45

Lunch Break, Networking and visit the Exhibition

 13:45-15:15

 Session VII: Cardiovascular Outcome Studies Part 2: Design, Interpretation and Translation
   13:45-14:15 
 Next Generation of Diabetes Trials (Round Table)
 Neda  Rasouli, USA, Ralph DeFronzo, USA

 14:15-14:30 
 Considerations in the Selection and Analysis of Multiple Outcomes
 John Lachin, USA

 14:30-14:45 
 Using Long-term Studies to Assess Medication Safety; What are the Issues?  
 Itamar Raz, Israel

 14:45-15:00
 Diabetic Kidney Disease
 Hiddo J. Lambers Heerspink, Netherlands

 15:00-15:15
 Interpretation and Translation of Cardiovascular studies in clinical practice
 Neda  Rasouli, USA

 15:15-15:45

 Networking Break and visit the Exhibition

15:45-16:45

 Session VIII: Special National Program to Enhance Drug Development
   15:45-16:05
 Special National Program to Enhance Drug Development 
 
 16:25-16:45
 Panel Discussion

16:45-17:00

 Congress Closing